PharmiWeb.com - Global Pharma News & Resources

Pharmaco - Press Releases

Date Title Company
01-Apr-2025 EVERSANA Joins Veeva AI Partner Program EVERSANA
01-Apr-2025 eXmoor Pharma Strengthens Board with Appointment of Dr James Miskin as Non-Executive Director eXmoor Pharma
01-Apr-2025 Mainz Biomed Reports 2024 Financial Results and Provides Corporate Update Mainz BioMed N.V.
01-Apr-2025 Lonza Implements its Simplified and Streamlined Operating Model Lonza Group AG
01-Apr-2025 Immunic, Inc. to Participate in Scientific and Industry Conferences in April Immunic AG
01-Apr-2025 Nxera Pharma Announces Appointments to its Executive Leadership Team Nxera Pharma
01-Apr-2025 UCB presents key data from Alzheimer’s and Parkinson’s disease research programs at AD/PD 2025 UCB
01-Apr-2025 AEVIS VICTORIA SA - The hotel branch of AEVIS VICTORIA recorded strong growth in 2024, driven by the quality of its assets and the strength of its integrated model. AEVIS VICTORIA SA
01-Apr-2025 Newron presents 2024 financial results and provides 2025 outlook Newron Pharmaceuticals S.p.A.
01-Apr-2025 Lonza Completes its Share Buyback Program Lonza Group AG
31-Mar-2025 OKYO Pharma Announces Positive Data in Long-Term Stability of Urcosimod OKYO Pharma
31-Mar-2025 APONTIS PHARMA with significant sales and earnings increase in 2024 financial year – squeeze-out and merger planned APONTIS PHARMA AG
31-Mar-2025 RYBREVANT®▼ (amivantamab) plus LAZCLUZE®▼ (lazertinib) demonstrates significant overall survival benefit in patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations versus osimertinib Johnson & Johnson
31-Mar-2025 MAJOR BREAKTHROUGH IN RESPIRATORY DIAGNOSTICS SET TO TRANSFORM NHS LUNG CARE TidalSense
31-Mar-2025 Qfitlia approved as the first therapy in the US to treat hemophilia A or B with or without inhibitors Sanofi
31-Mar-2025 Ozempic® (once-weekly semaglutide 1.0 mg) shown to improve walking distance and quality of life in adults with type 2 diabetes and peripheral artery disease (PAD) at ACC 2025 Novo Nordisk
31-Mar-2025 Biotest AG: Delisting agreement and announced delisting tender offer Biotest AG
31-Mar-2025 Drägerwerk AG & Co. KGaA: Dräger increases net profit in fiscal year 2024 and raises dividend Drägerwerk AG & Co. KGaA
31-Mar-2025 Biotest AG increases sales by 6% in financial year 2024 Biotest AG
31-Mar-2025 BIOVERSYS ANNOUNCES IMPORTANT BV100 PATENT GRANTED BY CHINESE PATENT OFFICE BioVersys AG